Altered oxidant and antioxidant levels are associated with vascular stiffness and diabetic kidney disease in type 1 diabetes after exposure to acute and chronic hyperglycemia.
Humans
Diabetes Mellitus, Type 1
/ blood
Male
Female
Diabetic Nephropathies
/ blood
Hyperglycemia
/ blood
Oxidative Stress
Antioxidants
/ metabolism
Adult
Biomarkers
/ blood
Vascular Stiffness
Case-Control Studies
Middle Aged
Blood Glucose
/ metabolism
Malondialdehyde
/ blood
Glycated Hemoglobin
/ metabolism
Reactive Oxygen Species
/ blood
Finland
/ epidemiology
Acute Disease
Oxidants
/ blood
Albuminuria
/ blood
Superoxide Dismutase
/ blood
Chronic Disease
Antioxidant capacity
Arterial stiffness
Diabetes
Diabetic kidney disease
Hyperglycemia
Oxidative stress
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
13
05
2024
accepted:
30
08
2024
medline:
29
9
2024
pubmed:
29
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Hyperglycemia-induced oxidative stress is a well-established pathological mediator of vascular complications in diabetes. We assessed plasma oxidant and antioxidant levels in response to acute and chronic hyperglycemia in relation to vascular stiffness and varying degrees of kidney disease in type 1 diabetes individuals. The acute hyperglycemia study included 22 type 1 diabetic individuals with normal albumin excretion rate (AER) and 13 non-diabetic controls. These individuals received an acute glucose challenge during a 120-minute hyperglycemic clamp. The chronic hyperglycemia study included 118 type 1 diabetic individuals with chronically low (n = 60) or high (n = 58) HbA1c concentrations and varying degrees of diabetic kidney disease (DKD) classified as normal, moderate, or severe albuminuria (AER). Levels of malondialdehyde (MDA), reactive oxygen metabolites (ROMs), total antioxidant capacity (TAC), biological antioxidant potential (BAP) and superoxide dismutase (SOD) were measured from plasma or serum samples in the FinnDiane study. Levels of MDA (p < 0.01) and ROMs (p < 0.01) were elevated in type 1 diabetes individuals compared to non-diabetic controls at baseline. Acute hyperglycemia further increased MDA levels (p < 0.05) and sustained the elevation of ROMs in type 1 diabetes individuals. Acute hyperglycemic challenge impaired TAC in both non-diabetic (p < 0.05) and type 1 diabetes (p < 0.01) individuals compared to baseline whereas BAP was increased (p < 0.05) with no difference observed in non-diabetic controls. There was a positive association between high circulating MDA and AIx (r2 = 0.611, p = 0.05), and between delta ROMs and delta AIx (r2 = 0.955, p = 0.014) in combined analysis of individuals with type 1 diabetes and non-diabetic controls. Type 1 diabetes individuals with varying status of DKD, showed elevated levels of ROMs in those with high HbA1c compared to their counterpart with low HbA1c (p < 0.05). Individuals with severe albuminuria showed elevated ROM levels (p < 0.01) and depressed antioxidant capacity (p < 0.01) compared to those with normal AER of comparable HbA1c concentrations. Biomarkers of oxidative stress are associated with vascular stiffness and DKD following acute and chronic hyperglycemic exposure and may provide added value to HbA1c in understanding disease pathology, predicting risk and assessing the status of secondary complications of type 1 diabetes.
Sections du résumé
BACKGROUND
BACKGROUND
Hyperglycemia-induced oxidative stress is a well-established pathological mediator of vascular complications in diabetes. We assessed plasma oxidant and antioxidant levels in response to acute and chronic hyperglycemia in relation to vascular stiffness and varying degrees of kidney disease in type 1 diabetes individuals.
METHODS
METHODS
The acute hyperglycemia study included 22 type 1 diabetic individuals with normal albumin excretion rate (AER) and 13 non-diabetic controls. These individuals received an acute glucose challenge during a 120-minute hyperglycemic clamp. The chronic hyperglycemia study included 118 type 1 diabetic individuals with chronically low (n = 60) or high (n = 58) HbA1c concentrations and varying degrees of diabetic kidney disease (DKD) classified as normal, moderate, or severe albuminuria (AER). Levels of malondialdehyde (MDA), reactive oxygen metabolites (ROMs), total antioxidant capacity (TAC), biological antioxidant potential (BAP) and superoxide dismutase (SOD) were measured from plasma or serum samples in the FinnDiane study.
RESULTS
RESULTS
Levels of MDA (p < 0.01) and ROMs (p < 0.01) were elevated in type 1 diabetes individuals compared to non-diabetic controls at baseline. Acute hyperglycemia further increased MDA levels (p < 0.05) and sustained the elevation of ROMs in type 1 diabetes individuals. Acute hyperglycemic challenge impaired TAC in both non-diabetic (p < 0.05) and type 1 diabetes (p < 0.01) individuals compared to baseline whereas BAP was increased (p < 0.05) with no difference observed in non-diabetic controls. There was a positive association between high circulating MDA and AIx (r2 = 0.611, p = 0.05), and between delta ROMs and delta AIx (r2 = 0.955, p = 0.014) in combined analysis of individuals with type 1 diabetes and non-diabetic controls. Type 1 diabetes individuals with varying status of DKD, showed elevated levels of ROMs in those with high HbA1c compared to their counterpart with low HbA1c (p < 0.05). Individuals with severe albuminuria showed elevated ROM levels (p < 0.01) and depressed antioxidant capacity (p < 0.01) compared to those with normal AER of comparable HbA1c concentrations.
CONCLUSIONS
CONCLUSIONS
Biomarkers of oxidative stress are associated with vascular stiffness and DKD following acute and chronic hyperglycemic exposure and may provide added value to HbA1c in understanding disease pathology, predicting risk and assessing the status of secondary complications of type 1 diabetes.
Identifiants
pubmed: 39342285
doi: 10.1186/s12933-024-02427-4
pii: 10.1186/s12933-024-02427-4
doi:
Substances chimiques
Antioxidants
0
Biomarkers
0
Blood Glucose
0
hemoglobin A1c protein, human
0
Malondialdehyde
4Y8F71G49Q
Glycated Hemoglobin
0
Reactive Oxygen Species
0
Oxidants
0
Superoxide Dismutase
EC 1.15.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
350Informations de copyright
© 2024. The Author(s).
Références
Jha JC, Gray SP, Barit D, Okabe J, El-Osta A, Namikoshi T, Thallas-Bonke V, Wingler K, Szyndralewiez C, Heitz F, Touyz RM, Cooper ME, Schmidt HH, Jandeleit-Dahm KA. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol. 2014;25:1237–54.
doi: 10.1681/ASN.2013070810
pubmed: 24511132
pmcid: 4033375
Di Marco E, Jha JC, Sharma A, Wilkinson-Berka JL, Jandeleit-Dahm KA, de Haan JB. Are reactive oxygen species still the basis for diabetic complications? Clin Sci. 2015;129:199–216.
doi: 10.1042/CS20150093
Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51:183–90.
doi: 10.1007/s00125-007-0842-6
pubmed: 17994218
Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35:2076–82.
doi: 10.2337/dc12-0199
pubmed: 22688551
pmcid: 3447848
Menon BB, Pathare NA. An in vitro evaluation of antibiotic combinations for urinary tract infections in patients with diabetes mellitus. Indian J Pathol Microbiol. 2004;47:565–8.
pubmed: 16295399
Gordin D, Forsblom C, Rönnback M, Parkkonen M, Wadén J, Hietala K, Groop PH. Acute hyperglycaemia induces an inflammatory response in young patients with type 1 diabetes. Ann Med. 2008;40:627–33.
doi: 10.1080/07853890802126547
pubmed: 18608123
Di Marco E, Gray SP, Jandeleit-Dahm K. Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature. Front Endocrinol. 2013;4:68.
doi: 10.3389/fendo.2013.00068
Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care. 2010;33(7):1529–35.
doi: 10.2337/dc09-0354
pubmed: 20587723
pmcid: 2890354
Munshi MN, Slyne C, Segal AR, Saul N, Lyons C, Weinger K. Simplification of insulin regimen in older adults and risk of Hypoglycemia. JAMA Intern Med. 2016;176(7):1023–5.
doi: 10.1001/jamainternmed.2016.2288
pubmed: 27273335
Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest. 2001;108(4):635–6.
doi: 10.1172/JCI13727
pubmed: 11518739
pmcid: 209408
Gordin D, Wadén J, Forsblom C, Thorn LM, Rosengard-Barlund M, Heikkila O, Saraheimo M, Tolonen N, Hietala K, Soro-Paavonen A, Salovaara L, Mäkinen VP, Peltola T, Bernardi L, Groop PH. FinnDiane Study Group. Arterial stiffness and vascular complications in patients with type 1 diabetes: the Finnish Diabetic Nephropathy (FinnDiane) Study. Ann Med. 2012;44:196–204.
doi: 10.3109/07853890.2010.530681
pubmed: 21047152
Savikj M, Kostovski E, Lundell LS, Iversen PO, Massart J, Widegren U. Altered oxidative stress and antioxidant defence in skeletal muscle during the first year following spinal cord injury. Physiol Rep. 2019;7(16):e14218.
doi: 10.14814/phy2.14218
pubmed: 31456346
pmcid: 6712236
Patente TA, Mohammedi K, Bellili-Munoz N, Driss F, Sanchez M, Fumeron F, Roussel R, Hadjadj S, Corrêa-Giannella ML, Marre M, Velho G. Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes. Free Radic Biol Med. 2015;86:16–24.
doi: 10.1016/j.freeradbiomed.2015.04.002
pubmed: 25862415
Colette C, Monnier L. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res. 2007;39(9):683–6.
doi: 10.1055/s-2007-985157
pubmed: 17846977
Waden J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH. Finnish Diabetic Nephropathy Study G. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes. 2009;58:2649–55.
doi: 10.2337/db09-0693
pubmed: 19651819
pmcid: 2768180
Hitomi Y, Masaki N, Ishinoda Y, Ido Y, Iwashita M, Yumita Y, Kagami K, Yasuda R, Ikegami Y, Toya T, Namba T, Nagatomo Y, Takase B, Adachi T. Effectiveness of the d-ROMs oxidative stress test to predict long-term cardiovascular mortality. Int J Cardiol. 2022;354:43–7.
doi: 10.1016/j.ijcard.2022.03.001
pubmed: 35257723
Matsuura T, Kaneko H, Takayama K, Shibata R, Kataoka K, Ito S, Tsunekawa T, Shimizu H, Suzumura A, Namba R, Ito Y, Murohara T, Terasaki H. Diacron reactive oxygen metabolites and biological antioxidant potential tests for patients with age-related macular degeneration. BMC Ophthalmol. 2020;20(1):56.
doi: 10.1186/s12886-020-01334-y
pubmed: 32070305
pmcid: 7027115
Ferreira MT, Leite NC, Cardoso CR, Salles GF. Correlates of aortic stiffness progression in patients with type 2 diabetes: importance of glycemic control: the Rio De Janeiro type 2 diabetes cohort study. Diabetes Care. 2015;38:897–904.
doi: 10.2337/dc14-2791
pubmed: 25678104
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. EMPA-REG OUTCOME investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.
doi: 10.1056/NEJMoa1515920
pubmed: 27299675
Picazo A, Jiménez-Osorio AS, Zúñiga-Mejía P, Pedraza-Chaverri J, Monroy A, Rodríguez-Arellano ME, Barrera-Oviedo D. Hypoglycemic drugs induce antioxidant aldehyde dehydrogenase activity and remain high in patients with glycemic control in type 2 diabetes. Eur J Pharmacol. 2017;800:57–62.
doi: 10.1016/j.ejphar.2017.02.027
pubmed: 28216053
Güven M, Onaran I, Ulutin T, Sultuybek G, Hatemi H. Effect of acute hyperglycemia on potassium (86Rb+) permeability and plasma lipid peroxidation in subjects with normal glucose tolerance. J Endocrinol Invest. 2001;24(4):231-5. Corrected and republished in: J Endocrinol Invest 2001;24(7):549– 53.
İhsan B, Türkan Y, Handan A. Is oxidative stress a consequence of hyperglycemia? Or is Hyperglycemia the consequence of oxidative stress? Or are both caused by Insulin Resistance? Int Archives Endocrinol Clin Res 2021.
Mah E, Noh SK, Ballard KD, Matos ME, Volek JS, Bruno RS. Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine:arginine. J Nutr. 2011;141(11):1961–8.
doi: 10.3945/jn.111.144592
pubmed: 21940510
Karasu C. Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment. Open Cardiovasc Med J. 2010;4:240–56.
doi: 10.2174/1874192401004010240
pubmed: 21270942
pmcid: 3026340
Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A. 2006;103(8):2653–8.
doi: 10.1073/pnas.0511154103
pubmed: 16477035
pmcid: 1413838
Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative stress in atherosclerosis. Curr Atheroscler Rep. 2017;19(11):42.
doi: 10.1007/s11883-017-0678-6
pubmed: 28921056
Cao G, Prior RL. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem. 1998;44:1309–15.
doi: 10.1093/clinchem/44.6.1309
pubmed: 9625058
Kumawat M, Sharma TK, Singh I, Singh N, Ghalaut VS, Vardey SK, Shankar V. Antioxidant enzymes and lipid peroxidation in type 2 diabetes Mellitus patients with and without Nephropathy. N Am J Med Sci. 2013;5:213–9.
doi: 10.4103/1947-2714.109193
pubmed: 23626958
pmcid: 3632026
El-Awady MS, El-Agamy DS, Suddek GM, Nader MA. Propolis protects against high glucose-induced vascular endothelial dysfunction in isolated rat aorta. J Physiol Biochem. 2014;70(1):247–54.
doi: 10.1007/s13105-013-0299-7
pubmed: 24234058
Yildirim T, Göçmen AY, Özdemir ZT, Börekci E, Turan E, Aral Y. The effect of hyperglycemic peak induced by oral glucose tolerance test on the oxidant and antioxidant levels. Turk J Med Sci. 2019;49(6):1742–7.
pubmed: 31655528
pmcid: 7518681
Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res. 1998;39:1529–42.
doi: 10.1016/S0022-2275(20)32182-9
pubmed: 9717713
Morandi A, Corradi M, Orsi S, Piona C, Zusi C, Costantini S, Marigliano M, Maffeis C. Oxidative stress in youth with type 1 diabetes: not only a matter of gender, age, and glycemic control. Diabetes Res Clin Pract. 2021;179:109007.
doi: 10.1016/j.diabres.2021.109007
pubmed: 34411622
Okada S, Okada J, Yamada E, Saito T, Yamada M. 435-P: Elevated one-hour post-challenge glucose levels associated with increased arterial stiffness. Diabetes. 2019;68(Supplement 1).
Gordin D, Ronnback M, Forsblom C, Heikkila O, Saraheimo M, Groop PH. Acute hyperglycaemia rapidly increases arterial stiffness in young patients with type 1 diabetes. Diabetologia. 2007;50:1808–14.
doi: 10.1007/s00125-007-0730-0
pubmed: 17611734
Gomez-Marcos MA, Blazquez-Medela AM, Gamella-Pozuelo L, Recio-Rodriguez JI, Garcia-Ortiz L, Martinez-Salgado C. Serum superoxide dismutase is Associated with Vascular structure and function in Hypertensive and Diabetic patients. Oxid Med Cell Longev. 2016;2016:9124676.
doi: 10.1155/2016/9124676
pubmed: 26635913
McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR. ACCT investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol. 2005;46(9):1753–60.
doi: 10.1016/j.jacc.2005.07.037
pubmed: 16256881
Molitch ME, Steffes MW, Cleary PA, Nathan DM. Baseline analysis of renal function in the Diabetes Control and complications Trial. The Diabetes Control and Complications Trial Research Group [corrected]. Kidney Int. 1993;43:668–74.
doi: 10.1038/ki.1993.96
pubmed: 8455366
Frontoni S, Di Bartolo P, Avogaro A, Bosi E, Paolisso G, Ceriello A. Glucose variability: an emerging target for the treatment of diabetes mellitus. Diabetes Res Clin Pract. 2013;102(2):86–95.
doi: 10.1016/j.diabres.2013.09.007
pubmed: 24128999
Wightman SS, Sainsbury CAR, Jones GC. Visit-to-visit HbA1c variability and systolic blood pressure (SBP) variability are significantly and additively associated with mortality in individuals with type 1 diabetes: an observational study. Diabetes Obes Metab. 2018;20:1014–7.
doi: 10.1111/dom.13193
pubmed: 29266630
Chemlal H, Bensalem S, Bendiab K, Azzar M, Benberkane A, Lalaoui K, Iguer-Ouada M, Bournine L. High HbA
doi: 10.1111/and.13902
pubmed: 33167064
Chen X, Liu W, Xiao J, Zhang Y, Chen Y, Luo C, Huang Q, Peng F, Gong W, Li S, He X, Zhuang Y, Wu N, Liu Y, Wang Y, Long H. FOXO3a accumulation and activation accelerate oxidative stress-induced podocyte injury. FASEB J. 2020;34(10):13300–16.
doi: 10.1096/fj.202000783R
pubmed: 32786113
Ziegler D, Sohr CG, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care. 2004;27(9):2178–83.
doi: 10.2337/diacare.27.9.2178
pubmed: 15333481